Knome, a US-based life sciences company specialising in genome research, appointed Martin Tolar as its chief executive officer on Monday. Tolar previously held the same position at biopharmaceutical company Normoxys. Prior to helming Normoxys, Tolar held executive positions at pharmaceutical companies CoMentis and Pfizer, where he played a significant role in the corporation’s acquisition of Rinat Neurosciences in 2006. Founded in 2007, Knome works on interpreting human genomes likely to govern particular diseases and responses to drug treatments. Academic, pharmaceutical and biotechnology researchers outsource the interpretation part of their work to Knome, while clinics are able to purchase large-scale data systems to aid their work. France-based diagnostics company BioMerieux invested $5m in Knome, in April 2010, as part of a strategic collaboration involving the development of in vitro diagnostic tools. Knome attracted a further $5m in August 2011 but did not disclose the source of the funding. Tolar said: "I am delighted to join Knome. The company has superior technology and world-class genome interpretation capabilities that I believe will make a major impact on the way we diagnose and treat diseases, develop drugs, and make lifestyle decisions. We are on the cusp of the genomic and personalized medicine revolution-right when the cost of sequencing has reached a point where the application of genetic information is feasible across a host of opportunities. "I expect that Knome will be a leader in this transformation as we broaden our business from academic research into expanded applications for drug development at pharmaceutical and biotechnology companies; the treatment of individual patients at hospitals and clinics; and a wide range of consumer applications." Tolar’s hiring was made as Knome made additional rotations on its board. Founding chief executive Jorge Conde will become chief strategy officer, while Jonas Lee, also a founding member of Knome’s board and its head of consumer genomics, will expand his role to include chief marketing officer.
- News & Analysis
- Global Corporate Venturing
- Global University Venturing
- Latest News
- Deal Data
- Community & Events
Tolar becomes a part of Knome’s DNA
Jan 12, 2012 • Robert Lavine
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
Featured ContentFUNDING ROUND DATA Which corporates are backing which startups? Search our corporate deal database.
FUNDING ROUND DATA
Which corporates are backing which startups? Search our corporate deal database.NOMINATE Nominations for the GCV Powerlist 2024 are now open
Nominations for the GCV Powerlist 2024 are now openEventsWebinar: Startups and Strategics – What works and what doesn’tEventsGCV Institute: Landing the Value of Corporate VenturingTop News
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.test reg